TRT Prior Authorization: What It Means, What Insurers Require, and How to Cut Your Costs

What Is a Prior Authorization for TRT?

A prior authorization (PA) is a formal insurer review that must be completed and approved before the plan will pay for testosterone replacement therapy. Your prescribing clinician submits clinical documentation to the payer, the payer compares it against its internal coverage criteria, and the plan either approves, denies, or requests more information. The whole process can take 3 to 14 business days under standard review, or 24 to 72 hours under urgent review. Skipping it almost always means the pharmacy claim is rejected at the point of sale.

The requirement exists because the FDA approves testosterone products for classic hypogonadism, not age-related testosterone decline alone. The FDA's approved labeling for testosterone products restricts the indication to "conditions associated with a deficiency or absence of endogenous testosterone," which insurers interpret strictly. Payers use that label language to write their PA criteria, so the clinical bar is specific and not negotiable.

The Endocrine Society's 2018 clinical practice guideline states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness and recommend confirmatory testing on at least two occasions." [1] That two-test requirement is the single most common reason a first PA submission is returned incomplete.

Exact Lab and Clinical Requirements Most Insurers Demand

Most commercial payers require the same core evidence package. Getting it right the first time cuts denial rates substantially.

Serum testosterone. Two separate fasting morning draws (collected between 7 a.m. and 10 a.m.) showing total testosterone below 300 ng/dL. Some plans use 280 ng/dL as the cutoff. Free testosterone below 65 pg/mL may substitute if SHBG is elevated, per Endocrine Society guidance. [1]

LH and FSH. These distinguish primary hypogonadism (elevated LH/FSH, testicular origin) from secondary hypogonadism (low-normal LH/FSH, pituitary or hypothalamic origin). Insurers want to see the classification documented. [2]

Prolactin. Required to rule out a prolactinoma when LH and FSH are low. The NIH MedlinePlus resource on hyperprolactinemia notes that prolactin levels above 200 ng/mL almost always indicate a pituitary adenoma that needs imaging before testosterone is started. [3]

PSA and hematocrit. Baseline safety labs. The Endocrine Society guideline recommends checking PSA and hematocrit before treatment initiation and at 3 to 6 months. [1] Payers use baseline PSA to exclude men with suspected prostate cancer, which is an absolute contraindication per FDA labeling. [4]

Symptom documentation. The clinician's note must list at least three symptoms of hypogonadism: low libido, fatigue, depressed mood, erectile dysfunction, decreased muscle mass, or increased body fat. Vague chart language like "patient feels tired" is routinely flagged. Quantified tools such as the Androgen Deficiency in Aging Males (ADAM) questionnaire or the AMS scale strengthen the submission. [5]

Cause of hypogonadism. Insurers generally want a documented etiology: Klinefelter syndrome, bilateral orchiectomy, pituitary tumor, radiation history, or another recognized cause. Age-related decline without a structural or genetic diagnosis is the most common reason commercial payers deny coverage entirely. [6]

How to Submit a TRT Prior Authorization That Gets Approved

The submission itself is straightforward. Problems almost always come from missing pieces, not from the process being uniquely difficult.

Your clinician (or their MA/PA) completes the payer-specific PA form. For most large commercial plans, this can be done through CoverMyMeds or directly through the plan portal. The submission needs to attach the two testosterone lab reports with collection timestamps, the office note documenting symptoms, the LH/FSH/prolactin results, the baseline PSA and hematocrit, and the specific testosterone product and dose being requested.

Turnaround times by plan type run roughly as follows. Most commercial PPO plans complete standard reviews within 3 to 5 business days. Medicare Advantage plans have a federally mandated 14-calendar-day limit for standard reviews and 72 hours for urgent requests, per CMS guidance on Part D coverage determinations. [7] If the plan does not respond within its stated window, that non-response is treated as a denial and you have the right to appeal immediately.

If the PA is denied, ask the plan for the specific denial reason in writing. Common denial codes include "diagnosis not covered," "labs insufficient," and "alternative therapy required first." An appeal that directly rebuts each denial reason with supporting clinical literature typically succeeds 40 to 60% of the time on the first round. The American Urological Association's position statement on testosterone deficiency can anchor an appeal argument because it is a named guideline document, not just a peer-reviewed opinion. [8]

Insurance Coverage for TRT: What Plans Actually Pay

Coverage varies sharply across plan types. Knowing which tier your plan places testosterone in changes your cost estimate by hundreds of dollars per year.

Commercial employer plans. Most large employer plans cover FDA-approved testosterone formulations (cypionate, enanthate, undecanoate, and transdermal gels) when PA criteria are met. Formulary placement matters. Generic testosterone cypionate injection is almost always Tier 1 or Tier 2, meaning a $10, $45 copay per fill. Brand-name AndroGel or Testim typically lands on Tier 3 or Tier 4, meaning 30 to 50% coinsurance. A 2021 analysis published in JAMA Internal Medicine found that prior authorization requirements are associated with significant treatment delays averaging 3.4 days, and that clinicians spend a mean of 14.9 minutes completing each PA request. [9]

Medicaid. Coverage and PA criteria vary by state. Most state Medicaid programs cover testosterone injections for confirmed hypogonadism. Gels and patches are often not on formulary. Check your state's preferred drug list directly, as criteria change annually.

Medicare Part B vs. Part D. This distinction trips up many patients. Testosterone injections administered in a physician's office or infusion center bill under Part B. Self-administered injections filled at a pharmacy bill under Part D. The CMS Medicare Benefit Policy Manual covers the Part B injection rules in Chapter 15. [7] Part D plans cover FDA-approved testosterone formulations when they appear on the plan's formulary and PA criteria are satisfied. The out-of-pocket max under Part D's 2025 redesign is $2,000 per year, which caps catastrophic exposure for men on costly brand-name gels.

Medicare Advantage. These plans must cover at minimum the same drugs as traditional Medicare Part D but can apply additional PA requirements. A CMS data brief on Medicare Advantage prior authorization found that 99% of Medicare Advantage enrollees are in plans that use PA for at least some drug categories. [7]

What TRT Actually Costs Per Month Without Insurance

Cash prices for testosterone have dropped sharply over the past decade because generic formulations now dominate the injectable market. The numbers below reflect 2025 pharmacy pricing using GoodRx and manufacturer pricing data.

Testosterone cypionate injection (generic). A 10 mL vial at 200 mg/mL costs $30, $60 at most major pharmacies. At a standard starting dose of 100 mg intramuscularly every week, that vial lasts approximately 10 weeks, putting the medication cost alone at roughly $13, $25 per month. [10]

Testosterone enanthate injection (generic). Slightly higher at $40, $80 per 5 mL vial (200 mg/mL). Monthly cost at 100 mg/week is approximately $16, $30. [10]

AndroGel 1.62% (brand). Without insurance or a coupon, a 30-day supply runs $450, $600. AbbVie's patient assistance program can reduce this for qualifying patients, but eligibility is income-based. [4]

Testosterone undecanoate (Aveed, brand). A single 750 mg/3 mL injection is administered in-office. The drug itself bills at approximately $700 per dose (given at weeks 0, 4, and then every 10 weeks). Per-month cost across a maintenance cycle is roughly $280, but the cost of the office visit adds to that. [4]

Clomiphene citrate (off-label for secondary hypogonadism). Some online TRT clinics prescribe 25 to 50 mg clomiphene 3 to 5 times per week as an alternative to exogenous testosterone, especially for men who want to preserve fertility. Generic clomiphene costs $15, $40 per month. Insurance rarely covers it for this indication because it is off-label, but the cash price is low. [11]

Online TRT clinic pricing. Telehealth TRT platforms typically bundle medication, shipping, lab work, and clinician visits. Pricing ranges from $99 to $249 per month depending on the platform and whether labs are included. The medication component alone (usually testosterone cypionate or enanthate) represents $13, $30 of that bundle cost. The remainder covers medical oversight, which is a legitimate clinical expense given that untreated hypogonadism is associated with increased cardiovascular risk. A 2021 meta-analysis in The Journal of Clinical Endocrinology and Metabolism (N = 24,109 across 11 studies) found that testosterone therapy in men with confirmed hypogonadism was associated with reduced major adverse cardiovascular events compared to untreated controls. [12]

Medicare and TRT: A Closer Look at Part D Coverage

Medicare Part D plans cover testosterone when it appears on the plan's formulary and the enrollee meets PA criteria. Standard Part D PA criteria for testosterone mirror commercial plan requirements: two morning testosterone levels below 300 ng/dL, documented symptoms, and a recognized etiology.

The CMS 2025 Part D formulary guidance requires that all Part D plan formularies include at least two drugs in each therapeutic category. [7] Testosterone injectable formulations satisfy this requirement, so most Part D plans carry at least generic testosterone cypionate and one other formulation.

One practical issue for Medicare patients: compound testosterone formulations from 503A compounding pharmacies are not FDA-approved finished drug products. Medicare Part D does not cover compounded medications, per FDA policy on compounded drug products. [4] Men who obtain testosterone from compounding pharmacies pay entirely out of pocket, even if they have Part D coverage. That distinction is rarely explained at the point of prescribing.

For men enrolled in Medicare who also have a Medicare Supplement (Medigap) policy, the Medigap plan covers Part A and Part B cost-sharing but does not add drug coverage. Drug coverage must come from a standalone Part D plan or a Medicare Advantage plan with drug coverage (MAPD).

Using an HSA or FSA to Pay for TRT

A Health Savings Account (HSA) or Flexible Spending Account (FSA) can be used to pay for prescription testosterone, lab draws, and medically necessary office visits related to hypogonadism management. The IRS defines qualified medical expenses in Publication 502, which includes "prescription drugs" broadly. [13] Because testosterone prescribed for diagnosed hypogonadism is a prescription medication for a medical condition, it qualifies.

Compounded testosterone from a 503A pharmacy qualifies as long as it is prescribed by a licensed clinician. Cosmetic use of testosterone (for body composition improvement in the absence of a diagnosis) would not qualify, and using HSA funds for non-qualified expenses triggers a 20% penalty plus income tax on the withdrawal.

The annual HSA contribution limit for 2025 is $4,300 for self-only coverage and $8,550 for family coverage, per IRS Rev. Proc. 2024-25. [13] For a man paying $149 per month cash for a bundled TRT program, that is $1,788 per year, well within the self-only contribution limit. Pre-tax HSA dollars effectively reduce the real cost by the payer's marginal tax rate, which is 22 to 24% for most middle-income earners.

What to Do When TRT Is Denied or Excluded

Some plans specifically exclude testosterone therapy for age-related hypogonadism (sometimes called "late-onset hypogonadism") as a plan design choice, not a PA determination. A denial based on a plan exclusion is different from a PA denial. An exclusion cannot be appealed on medical necessity grounds because the plan simply does not cover the service.

In that situation, the realistic options are:

Switch to a generics-only cash-pay model. Generic testosterone cypionate at $13, $25 per month is inexpensive enough that insurance coverage may not change the calculus meaningfully, especially when PA-related delays and administrative burden are factored in.

Check the External Appeal process. Most states require that health plans allow an external independent review for medical necessity denials. PA denials (not exclusions) qualify. A Commonwealth Fund analysis of external appeals found that external reviewers overturn approximately 39 to 59% of denied claims when the appeal is complete and well-documented. [14]

Request a peer-to-peer review. The prescribing clinician can request a direct phone call with the plan's medical director. This is separate from the formal appeal. Peer-to-peer reviews resolve 20 to 40% of denials before a formal appeal is needed, primarily because the plan's reviewer can clarify missing documentation rather than issue a hard denial. [14]

Use a GLP-1 comparison as use in appeals. The TRAVERSE trial (N = 5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement therapy in middle-aged and older men with hypogonadism did not increase the rate of major adverse cardiovascular events compared to placebo (HR 0.96 to 95% CI 0.83, 1.12). [15] Citing TRAVERSE in an appeal letter directly rebuts the common insurer argument that TRT carries unacceptable cardiovascular risk. That argument was used to justify denials for years before the trial reported.

Lab Monitoring During TRT and Why It Affects Your PA Renewals

Many PA approvals are issued for 12 months and require re-authorization. Missing follow-up labs is the most common reason a renewal PA is denied, not because the patient stopped responding, but because the documentation gap gives the insurer a procedural reason to require a new full submission.

The Endocrine Society recommends checking testosterone levels, hematocrit, and PSA at 3 to 6 months after starting treatment, then annually. [1] A 2020 review in the Journal of Clinical Endocrinology and Metabolism found that polycythemia (hematocrit above 54%) occurs in approximately 5.7% of men on testosterone injections, compared to 0.8% on gels, and that the risk is dose-dependent. [16] Insurers check for these monitoring labs as part of renewal PA because documented safety monitoring is part of their coverage criteria. Keeping a lab schedule reduces renewal friction substantially.